Zenas BioPharma, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $27.75
- 52-Week Range
- $13.50 – $44.60
- Market Cap
- $1.79B
- P/E (TTM)
- —
- EPS (TTM)
- -10.08
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 8.44
- PEG Ratio
- —
- Return on Equity
- -265.11%
- Return on Assets
- -36.77%
- Gross Margin
- 0.00%
- Operating Margin
- -2666.64%
- Profit Margin
- 0.00%
- Current Ratio
- 9.42
- Debt/Equity
- 1.42
- Total Debt
- $300.89M
- Free Cash Flow
- $-250.62M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.51B
Market Snapshot
About
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company leverages its expertise in T-cell biology to develop novel treatments targeting unmet medical needs. Zenas BioPharma aims to bring innovative therapies to patients with serious immune-mediated conditions.